Incretins (GLP-1 Receptor Agonists) and Polycystic Ovaries
Polycystic ovary syndrome (PCOS) is a widespread condition affecting women of reproductive age. A new class of medications called incretins (GLP1RAs) provides new opportunities for reducing obesity, hyperandrogenism, and insulin resistance in these patients. Promising results have been achieved, including metabolic improvements and benefits in women with PCOS using different GLP1RAs.
Authors
- Mauri José Piazza (ORCID: https://orcid.org/0000-0002-8351-7501)
Institutions
- Universidade Federal do Paraná (BR)
Publication Details
- Journal
- JBRA
- Published
- 2025-01-01
- DOI
- https://doi.org/10.5935/1518-0557.20250162
- Primary Topic
- Ovarian function and disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.00